公开(公告)号：US20250084189A1

公开(公告)日：2025-03-13

申请号：US18724813

申请日：2022-12-30

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Matthew Buchanan ,  Omar De Paolis ,  Weiheng Wang

IPC: C08B37/00 ,  A61K9/00 ,  A61K9/50

Abstract: Described herein are polysaccharide polymers comprising a saccharide moiety modified with a hydroxyl-modifying agent (e.g., a saccharide monomer of Formula (I)), as well as related compositions, hydrogels, implantable elements, therapeutic substances, including enzymes, antibodies, hormones, or blood clotting factors. Further provided methods of treating a disease, disorder, or condition in a subject by administering to the subject an implantable element or a pharmaceutical composition.

公开(公告)号：US20220349896A1

公开(公告)日：2022-11-03

申请号：US17764096

申请日：2020-09-25

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Richard Heidebrecht ,  Zoe Yin

IPC: G01N33/68 ,  G01N1/40 ,  G01N1/44 ,  C07K19/00 ,  G01N30/86 ,  G01N30/88

Abstract: Described herein are methods for evaluating polymer compositions comprising polymers modified with a polypeptide (e.g., a cell-binding polypeptide), including methods for determining polypeptide concentration.

公开(公告)号：US20210145759A1

公开(公告)日：2021-05-20

申请号：US17045127

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Matthias Alexander Oberli ,  Owen O'Connor ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: A61K9/50 ,  A61K35/28 ,  A61K35/30 ,  C07K14/755 ,  C07K14/62 ,  C12N9/64

Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20200263196A1

公开(公告)日：2020-08-20

申请号：US16651892

申请日：2018-09-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Robert James Miller ,  Matthias Alexander Oberli ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: C12N15/85 ,  C12N5/079 ,  A61K35/30 ,  C07K14/755 ,  C07K14/55 ,  C07K14/635 ,  A61K9/00 ,  A61K9/48 ,  A61K47/54

Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20250017864A1

公开(公告)日：2025-01-16

申请号：US18705759

申请日：2022-10-28

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Hozefa Bandukwala ,  Susan J. Drapeau ,  Lauren E. Jansen

IPC: A61K9/50 ,  A61K35/30 ,  A61K45/06 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26

Abstract: Described herein are hydrogel capsule compositions which comprise a population of hydrogel capsules and a pharmaceutically acceptable solution. The hydrogel capsules in the population comprise a hydrogel-forming polymer and encapsulate a plurality of cells.

公开(公告)号：US20250000788A1

公开(公告)日：2025-01-02

申请号：US18274134

申请日：2022-01-26

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Sofia Brites Boss ,  Christopher P. Hencken ,  Hozefa Bandukwala ,  Robert James Miller ,  Omid Veiseh ,  Devyn McKinley Smith

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/5685 ,  A61K31/573 ,  A61K31/58 ,  A61K35/545 ,  A61K38/13 ,  A61K38/17 ,  A61K38/20 ,  A61K47/61 ,  A61K47/69

Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.

公开(公告)号：US20230303502A1

公开(公告)日：2023-09-28

申请号：US18019664

申请日：2021-08-04

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Richard Heidebrecht ,  Christopher P. Hencken ,  Omar De Paolis ,  Weiheng Wang ,  Matthew Buchanan

IPC: C07D249/04 ,  C07D471/04 ,  C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14

CPC classification number: C07D249/04 ,  C07D471/04 ,  C07D487/04 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14

Abstract: Described herein are compounds of Formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof, related compositions and preparations thereof, as well as methods of making and using the same.

公开(公告)号：US20210145889A1

公开(公告)日：2021-05-20

申请号：US17045137

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Devyn McKinley Smith ,  David Peritt ,  Omid Veiseh ,  Richard Heidebrecht ,  Robert James Miller

IPC: A61K35/28 ,  A61K9/00 ,  A61K47/22 ,  A61K9/50 ,  A61L27/38 ,  A61K38/37 ,  A61K38/48 ,  C12N5/00 ,  A61K38/28 ,  C12N5/0775

Abstract: Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20240209336A1

公开(公告)日：2024-06-27

申请号：US18285102

申请日：2022-03-31

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Brian Richard Fluharty ,  Elina Makino

IPC: C12N9/40 ,  A61K9/00 ,  A61K9/48 ,  A61K35/30 ,  A61K38/47 ,  A61K47/36 ,  C12N5/079

CPC classification number: C12N9/2465 ,  A61K9/0024 ,  A61K9/4816 ,  A61K35/30 ,  A61K38/47 ,  A61K47/36 ,  C12N5/0621 ,  C12Y302/01022 ,  C12N2510/00

Abstract: Described herein are genetically modified cells derived from a human cell and which contain at least one exogenous transcription unit inserted into one or more specific open chromatin regions (OCRs), as well as compositions, pharmaceutical preparations, and implantable devices comprising the genetically modified cells, and methods of using the same for preventing or treating a disease, disorder, or condition.

公开(公告)号：US20240123040A1

公开(公告)日：2024-04-18

申请号：US18276010

申请日：2022-02-04

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Elina Makino ,  Erika Pearson

IPC: A61K38/46 ,  A61K9/50 ,  A61K35/30 ,  A61P3/00

CPC classification number: A61K38/465 ,  A61K9/5036 ,  A61K35/30 ,  A61P3/00 ,  C12Y204/99 ,  C12Y301/06012

Abstract: Described herein are mammalian cells engineered to express and secrete an ARSB protein and optionally a sialytransferase protein, as well as compositions, implantable devices and device preparations comprising the engineered cells, and methods of making and using the same for treating MPS VI disease.